Stroke
Conditions
Brief summary
Endovascular thrombectomy and intravenous thrombolysis have become key therapeutic approaches for acute ischemic stroke. However, due to time window limitations, many patients are unable to receive reperfusion therapy, and the majority only receive supportive treatment. Ischemic stroke-related complications, including edema and infection, gradually subside after 7 days post-stroke, with the patient's condition generally stabilizing. Endogenous repair mechanisms will play a critical role in the coming months. This study aims to predict prognostic biomarkers for ischemic stroke patients who have not undergone reperfusion therapy, using blood proteomics data. All samples in our study are derived from this experiment. Our goal is to elucidate the molecular mechanisms underlying post-reperfusion prognosis and to provide insights for optimizing stroke treatment strategies.
Interventions
DIAGNOSTIC_TESTThe blood Proteome Profiling
Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.
Sponsors
Capital Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18. * Clinical signs consistent with acute ischemic stroke (TOAST classification: large artery atherosclerosis) * 7 to 30 days from symptom onset.
Exclusion criteria
* Severe infection or multiple organ failure. * Untreated moderate or severe coronary artery stenosis, or a history of coronary artery bypass surgery. * Ongoing hemodialysis or peritoneal dialysis, or severe renal insufficiency characterized by a glomerular filtration rate (GFR) of less than 30 ml/min or serum creatinine levels exceeding 220 mmol/L (2.5 mg/dl). * Known intracranial aneurysm or cerebral arteriovenous malformation. * Malignant brain tumor or central nervous system (CNS) infection. * Pre-existing neurological or psychiatric conditions that could confound the neurological or functional assessments. * Baseline platelet count \<50 × 109/L. * Pregnancy or lactation at the time of admission.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Outcome Measures: | 3 months | Modified Rankin Scale score (mRS) at 90 days The Modified Rankin Scale (mRS) at 90 days was used to assess functional outcomes. The mRS is a widely utilized scale to measure the degree of disability or dependence in daily activities among stroke patients. Minimum value: 0 (indicating no symptoms or disability) Maximum value: 6 (indicating death) Interpretation: Higher scores represent worse outcomes, reflecting greater levels of disability or mortality. |
Countries
China
Outcome results
None listed